logo
ResearchBunny Logo
Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer

Medicine and Health

Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer

Z. Ding, Q. Li, et al.

This pilot study explores the promising safety and efficacy of the personalized neoantigen peptide-pulsed autologous dendritic cell vaccine (Neo-DCVac) for advanced lung cancer. With a well-tolerated profile and a notable objective response rate of 25%, this research could redefine treatment options for patients facing this challenging disease. Conducted by a dedicated team of researchers.

00:00
00:00
~3 min • Beginner • English
Abstract
Neoantigens are considered to be ultimate target of tumor immunotherapy due to their high tumor specificity and immunogenicity. Dendritic cell (DCs) vaccines based on neoantigens have exciting effects in treatment of some malignant tumors and are a promising therapeutic modality. Lung cancer is a lethal disease with the highest morbidity and mortality rate in the world. Despite the rapid development of targeted therapy and immune checkpoint inhibitors for lung cancer in recent years, their efficacy is still unsatisfactory overall. Therefore, there is an urgent unmet clinical need for lung cancer treatment. Here, we attempted to treat lung cancer using a personalized neoantigen peptide-pulsed autologous DC vaccine and conducted a single-arm, 2 medical centers, pilot study initiated by the investigator (ChiCTR-ONC-16009100, NCT02956551). The patients enrolled were patients with heavily treated metastatic lung cancer. Candidate neoantigens were derived from whole-exome sequencing and RNA sequencing of fresh biopsy tissues as well as bioinformatics analysis. A total of 12 patients were enrolled in this study. A total of 85 vaccine treatments were administered with a median value of 5 doses/person (range: 3-14 doses/person). In total, 12-30 peptide-based neoantigens were selected for each patient. All treatment-related adverse events were grade 1-2 and there were no delays in dosing due to toxic effects. The objective effectiveness rate was 25%; the disease control rate was 75%; the median progression-free survival was 5.5 months and the median overall survival was 7.9 months. This study provides new evidence for neoantigen vaccine therapy and new therapeutic opportunities for lung cancer treatment.
Publisher
Signal Transduction and Targeted Therapy
Published On
Jan 20, 2021
Authors
Zhenyu Ding, Qing Li, Rui Zhang, Li Xie, Yang Shu, Song Gao, Peipei Wang, Xiaoqing Su, Yun Qin, Yuelan Wang, Juemin Fang, Zhongzheng Zhu, Xuyang Xia, Guochao Wei, Hui Wang, Hong Qian, Xianling Guo, Zhibo Gao, Yu Wang, Yuquan Wei, Qing Xu, Heng Xu, Li Yang
Tags
neoantigen
dendritic cell vaccine
lung cancer
safety
efficacy
treatment
personalized medicine
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny